Down syndrome-associated acute lymphoblastic leukemia (DS-ALL) is a biologically distinct subtype with high rates of treatment-related mortality and relapse. Genomic profiling reveals frequent CRLF2 rearrangements, JAK-STAT pathway mutations, and high-risk subtypes such as BCR::ABL1-like disease. Conventional chemotherapy achieves remission but is limited by toxicity in DS patients. Recent advances in immunotherapy, including blinatumomab, inotuzumab ozogamicin, and CD19-directed CAR T-cell therapy, have shown significant efficacy and favorable tolerability in pediatric and adult DS-ALL. Blinatumomab and inotuzumab enable minimal residual disease clearance and serve as chemotherapy-sparing or bridging strategies, while CAR T-cell therapy offers curative potential and may reduce transplant reliance. Emerging approaches incorporating early immunotherapy, MRD-guided treatment, and chemotherapy-free regimens may improve survival and quality of life. Prospective DS-specific trials are essential to optimize therapy and close the outcome gap in this high-risk population.

01 Feb 2026·JCO Global Oncology

Evaluating Risk Factors for Early Mortality in Adult ALL in Brazil

Article

Author: de Azevedo, Pablo Dossi Nascimento ; Rocha, Vanderson ; Lange, Ana Paula Alencar de Lima ; Velloso, Elvira D.R.P. ; Losso, Lucca Marcon ; Rego, Eduardo M. ; Silva, Wellington F.

PURPOSE:

Adult ALL is typically treated with intensive chemotherapy although novel agents like blinatumomab and inotuzumab remain largely inaccessible in low- and middle-income countries (LMICs). Early mortality (EM) during induction is substantially higher in LMICs (10%-25%) than in high-income countries (<5%). This study aimed to identify EM risk factors in patients with adult ALL in LMICs to guide context-specific interventions.

METHODS:

A retrospective cohort study analyzed patients 15 years and older with newly diagnosed ALL between 2009 and 2023, regardless of the phenotype or Philadelphia status. EM was defined as death within 30 days of diagnosis.

RESULTS:

Among 203 patients (median age 36 years), the overall EM was 9.8% and 7.9% was younger than 50 years. Univariate analysis identified positive cerebral spinal fluid, cyclophosphamide during the prephase, low albumin, and obesity as associated with higher EM. In multivariable models, predictors of EM for the full cohort included age, albumin, cyclophosphamide use, and obesity. In patients 50 years and younger, only albumin and cyclophosphamide remained significant. After induction, 51.2% achieved complete response; 17.3% was unevaluable because of complications or death. Infection was common (72.9%). Sociodemographic variables were not associated with EM.

CONCLUSION:

EM was elevated, reflecting LMIC-specific challenges like late diagnosis and limited supportive care. Low albumin and prephase cyclophosphamide use were strongly linked to EM, likely via increased immunosuppression and infection risk. Findings stress the need for locally adapted protocols and simple risk markers to reduce EM in adult ALL.

28 Jan 2026·Leukemia & Lymphoma

Mini-hyper CVD-inotuzumab with asciminib as salvage therapy for ponatinib-refractory Ph + B-ALL and CML lymphoid blast crisis

Article

Author: Dua, Vikas ; Nathany, Shrinidhi ; Swaminathan, Anusha ; Danewa, Arun ; Rastogi, Neha ; Bhargava, Rahul ; Kumar, Nikhil M. M.

100 Deals associated with Inotuzumab

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	L01XC26	-

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Neoplasms	Clinical	-	Pfizer Inc.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


PS1377 (EHA2025)	Not Applicable	Refractory B Acute Lymphoblastic Leukemia CD22	68	Inotuzumab Ozogamicin (INO)	chzfkwtmcq(skjhzfpyhs) = Hematologic toxicity occurred in all patients, with 52.9% experiencing grade 3-4 events rryczebsgk (zyfbbcnkef ) View more	Positive	14 May 2025
PB2350 (EHA2025)	Not Applicable	Recurrent Childhood Acute Lymphoblastic Leukemia CD22 expression	26	Inotuzumab 1 mg/m^2	nlxkwkgkck(tdhkgmrlpw) = cxowbotjed qdbzexbzkb (ymzpeyesbh ) View more	Positive	14 May 2025
PB2350 (EHA2025)	Not Applicable		26	Inotuzumab 1.2 mg/m^2	nlxkwkgkck(tdhkgmrlpw) = iejfcaltgp qdbzexbzkb (ymzpeyesbh ) View more	Positive	14 May 2025
PF1161 (EHA2025)	Not Applicable	Refractory B Acute Lymphoblastic Leukemia	73	Inotuzumab-based regimen	gqxkmjmidw(ymaqsheziu) = plqamkdcre qfrirctdkv (vciwqxuqqn ) View more	Positive	14 May 2025
PF1161 (EHA2025)	Not Applicable	Refractory B Acute Lymphoblastic Leukemia	73	Tali-cel infusion	sfiafjryos(gqzwglacnr) = tiugxleltw rqatmrgcnv (ftanfnsibo, 1 - 74)	Positive	14 May 2025
ASH2024	Not Applicable	Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia	-	Inotuzumab	bqdfwbdtvd(wsecgbbewc) = iytepkqkah ouzmubpocf (zpvwkhfcnd ) View more	-	07 Dec 2024
ALL-808 (SOHO2024)	Phase 2	Recurrent Childhood Acute Lymphoblastic Leukemia	22	Mini-Hyper-CVD-Inotuzumab-Blinatumomab	gelgnbfsxk(rlrxjpavdq) = bubymkhggq uwcdycrqbe (tjfbqknwut ) View more	Positive	04 Sep 2024
EHA2023	Not Applicable	Precursor B-Cell Lymphoblastic Leukemia-Lymphoma	21	Two-dose regimen of inotuzumab	hfftechwdz(nklxggjhja) = Grade 1-3 hepatotoxicity occurred in 5 cases (23.8%) pxkcfcftqn (diovzorvyn )	-	08 Jun 2023
EHA2023	Phase 2	Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia	83	Mini-Hyper-CVD-Inotuzumab	tjtyaikjwr(qmggrojtme) = bgjjcimqqf wyvcvoeyem (qkyshavdeb ) View more	-	08 Jun 2023
EHA2023	Phase 2		83	Mini-Hyper-CVD-Inotuzumab+Blinatumomab	cuewccbbmk(azwpcyyrqq) = mcrxbaqvha dosfovvguw (netxroehgw ) View more	-	08 Jun 2023

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis